Kisho is an information platform, not a medical provider. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. All content is aggregated from publicly available sources (including ClinicalTrials.gov, PubMed, FDA.gov, and Orphanet) and is provided for informational purposes only. Clinical trial eligibility, treatment decisions, and any health-related actions should always be discussed with a qualified healthcare professional. Kisho does not endorse any specific therapy, organization, or clinical trial. Terms of use · Privacy policy
Bullous pemphigoid (BP) is the most common form of autoimmune bullous dermatosis.
Biomarker and diagnostic research for bullous pemphigoid has been reported in the published literature.
1 FDA-approved treatment is available for bullous pemphigoid, including DUPILUMAB (DUPIXENT, approved 2017). An additional 4 compounds hold orphan drug designation.
Brand Name | Generic Name | Mechanism | Approved | Market Status |
|---|---|---|---|---|
Estimated prevalence: 1-5 in 10,000 (Uncommon).
8 clinical trials registered, 3 recruiting. Interventions under study include drug therapy, other interventions, and biologic therapy. Pipeline includes 1 PHASE3, 2 PHASE1, 1 NA. Research is sponsored by a mix of industry and academic institutions.
NCT ID | Title | Phase | Sponsor | Status |
|---|---|---|---|---|
[NCT02753777](https://clinicaltrials.gov/study/NCT02753777) |
Data assembled from 5 of 12 sources · Last updated Nov 3, 2026, 2:35 AM UTC
European rare disease database
Genetic and Rare Diseases Info Center
DUPIXENT
DUPILUMAB |
— |
2017 |
Available |
The following drugs have received orphan drug designation from the FDA for bullous pemphigoid. Orphan designation reflects regulatory interest and does not indicate approval for treatment.
Brand Name | Generic Name | Sponsor | Designated | Exclusivity End | Designation Status |
|---|---|---|---|---|---|
rituximab | rituximab | ODDIFACT SAS | 2025 | — | Designated |
nomacopan | nomacopan | Akari Therapeutics Plc | 2019 | — | Designated |
bertilimumab | bertilimumab | Alexion Pharmaceuticals, Inc. | 2018 | — | Designated |
humanized IgG4 Monoclonal Antibody against total complement component 1, subcomponent s (C1s) | humanized IgG4 Monoclonal Antibody against total complement component 1, subcomponent s (C1s) | Recordati Rare Diseases Inc. | 2017 | — | Designated |
Gene therapy approaches for bullous pemphigoid have been reported in the published literature.
8 trials found
Autoimmune Blistering Diseases Study |
— |
University of Pennsylvania |
RECRUITING |
[NCT06371417](https://clinicaltrials.gov/study/NCT06371417) | Phase 1b Trial of RAY121 in Immunological Diseases (RAINBOW Trial) | PHASE1 | Chugai Pharmaceutical | RECRUITING |
[NCT05366127](https://clinicaltrials.gov/study/NCT05366127) | Validation of a Simplified Severity Score (Investigator Global Assessment: IGA) in Bullous Pemphigoid | — | University Hospital, Rouen | UNKNOWN |
[NCT06723106](https://clinicaltrials.gov/study/NCT06723106) | Phase 1b Long-term Extension Trial of RAY121 in Immunological Diseases (RAINBOW-LTE Trial) | PHASE1 | Chugai Pharmaceutical | ENROLLING_BY_INVITATION |
[NCT05954416](https://clinicaltrials.gov/study/NCT05954416) | FARD (RaDiCo Cohort) (RaDiCo-FARD) | — | Institut National de la Santé Et de la Recherche Médicale, France | RECRUITING |
250 publications have been identified in PubMed for bullous pemphigoid. Research spans Case Report / Case Series (28%), Review / Meta-Analysis (24%), and Epidemiology / Natural History (16%).
Research Type | Count | % of Total |
|---|---|---|
Patient case studies | 71 | 28% |
Research summaries | 59 | 24% |
Disease patterns and progression | 40 | 16% |
Laboratory research | 29 | 12% |
Other research | 21 | 8% |
Testing and diagnosis research | 18 | 7% |
Clinical study results | 9 | 4% |
New treatment approaches | 3 | 1% |
Didona D (2026). [PMID: 41994451](https://pubmed.ncbi.nlm.nih.gov/41994451/). *Front Med (Lausanne)*. [Case Report / Case Series]
Breakell T (2026). [PMID: 41979852](https://pubmed.ncbi.nlm.nih.gov/41979852/). *Dermatologie (Heidelb)*. [Case Report / Case Series]
Lawson K (2026). [PMID: 42022890](https://pubmed.ncbi.nlm.nih.gov/42022890/). *JID Innov*. [Basic Science / Preclinical]
Wang Z (2026). [PMID: 42094004](https://pubmed.ncbi.nlm.nih.gov/42094004/). *Front Immunol*. [Review / Meta-Analysis]
Alqahtani M (2026). [PMID: 41653489](https://pubmed.ncbi.nlm.nih.gov/41653489/). *Ann Dermatol Venereol*. [Epidemiology / Natural History]
Zou M (2026). [PMID: 41888879](https://pubmed.ncbi.nlm.nih.gov/41888879/). *Exp Dermatol*. [Epidemiology / Natural History]
Lei Y (2026). [PMID: 41870227](https://pubmed.ncbi.nlm.nih.gov/41870227/). *American journal of therapeutics*. [Case Report / Case Series]
Bohrnstedt G 2nd (2026). [PMID: 42282932](https://pubmed.ncbi.nlm.nih.gov/42282932/). *JAAD Case Rep*. [Case Report / Case Series]
Wang SH (2026). [PMID: 42094699](https://pubmed.ncbi.nlm.nih.gov/42094699/). *J Inflamm Res*. [Epidemiology / Natural History]
Albadri Z (2026). [PMID: 42186604](https://pubmed.ncbi.nlm.nih.gov/42186604/). *J Multimorb Comorb*. [Epidemiology / Natural History]
AI-curated news mentioning bullous pemphigoid
Updated Sep 22, 2026
A recent study explores the management of bullous pemphigoid and Norwegian scabies using a combination of dupilumab and ivermectin. This research could inform future treatment strategies for these rare skin conditions.
A recent case report highlights the coexistence of erythrodermic psoriasis and bullous pemphigoid, providing insights into the complexities of managing patients with multiple rare skin conditions. This finding may influence future research and treatment strategies for these diseases.
A case study highlights the use of deucravacitinib for managing both psoriasis vulgaris and bullous pemphigoid, demonstrating sustained dual disease control. This research may inform future treatment strategies for patients with overlapping dermatological conditions.